This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

This study has been completed.
Information provided by (Responsible Party):
Otsuka Beijing Research Institute Identifier:
First received: March 5, 2010
Last updated: October 10, 2012
Last verified: May 2011
To observe the safety/efficacy of tolvaptan for treatment of patients with hepatic cirrhosis with ascites and exploring the dosage-effect relations of the drug.

Condition Intervention Phase
Ascites Hepatic Cirrhosis Drug: Tolvaptan Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites

Resource links provided by NLM:

Further study details as provided by Otsuka Beijing Research Institute:

Primary Outcome Measures:
  • Body weight changes after 7 days of treatment (quantity of changes) [ Time Frame: from day1 to day7 ]

Secondary Outcome Measures:
  • Body weight change after 4 days of treatment (quantity of changes) [ Time Frame: from day1 to day4 ]
  • Waist circumference after 4 and 7 days of treatment (quantity and rate of changes) [ Time Frame: from day1 to day7 ]

Enrollment: 180
Study Start Date: April 2009
Study Completion Date: April 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. tolvaptan
15 mg, P.O., Qd, for 7 days,
Drug: Tolvaptan
tablet, 15 mg, Qd, for 7 days
Other Name: SAMSCA
Experimental: 2 tolvaptan
30 mg, P.O., Qd, for 7 days,
Drug: Tolvaptan
tablet, 30 mg, Qd, 7 days
Other Name: SAMSCA
Experimental: 3. Placebo
30mg,P.O.,Qd, for 7 days.
Drug: placebo
tablet, 30 mg, Qd, 7days.
Other Name: blank tablet

Detailed Description:
Tolvaptan is able to exert hydragogue diuretic effects (water diuresis) via inhibition of water reabsorption by renal collecting ducts without corresponding increase in electrolyte excretion. It has been confirmed that tolvaptan is able to increase urine volume without any adverse effects on renal functions.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites
  2. Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);
  3. During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;
  4. Ages: ≥18 and ≤75 years of age;
  5. Genders: men or women;
  6. Signed the Informed Consent Form.

Exclusion Criteria:

  1. Patients with the following diseases, complications or symptoms:

    • Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);
    • Malignant ascites;
    • Uncontrolled spontaneous bacterial peritonitis;
    • Patients are likely to experience alimentary tract hemorrhage during the trial;
    • Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4);
    • Anuria (daily urine volume below 100mL);
    • Dysuria resulting from urethral stricture, calculus and tumors.
  2. Patients with the following medical history:

    • Alimentary tract hemorrhage within 10 days prior to screening;
    • Cerebrovascular accident within 1 month prior to screening;
    • Gout attack within 1 month prior to screening;
    • Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)
  3. Systolic pressure below 90mmHg at screening;
  4. Patients with the following abnormalities in laboratory examinations at screening:

    Serum creatinine exceeds 2.5X upper limits of normal, serum Na+>145mmol/L (or exceeds upper limits of normal), serum K+>5.5mmol/L, uric acid>8.0mg/dL (476μmol/L), Child-pugh scale greater than 12.

  5. Patients cannot take drugs orally;
  6. Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable contraceptive measures;
  7. Patients received albumin or other blood preparations within 4 days prior to trial drug administration;
  8. Patients participated in clinical trials of other drugs within 1 month prior to screening;
  9. Patients participated in tolvaptan trials and took tolvaptan previously;
  10. Patients are unsuitable to participate in this trial in investigators' opinion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01349335

China, Shanghai
Renji hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China, 200001
Sponsors and Collaborators
Otsuka Beijing Research Institute
Principal Investigator: Minde Zeng RenJi Hospital
  More Information

Responsible Party: Otsuka Beijing Research Institute Identifier: NCT01349335     History of Changes
Other Study ID Numbers: 156-08-804-01
Study First Received: March 5, 2010
Last Updated: October 10, 2012

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs processed this record on August 16, 2017